#USA #Luxembourg #dBio #AI Wearables #Bert Hoyt

Former Nike VP Bert Hoyt Joins dBio as Board Advisor

In a significant move within the sports and health technology sectors, Bert Hoyt, a former Vice President and General Manager at Nike, has been appointed as a Board Advisor for Decentralized Biotechnology Intelligence Holding Group Inc. (dBio). With over 32 years of experience, Hoyt's background includes leadership roles at some of the world's leading sports brands, providing him with invaluable insights that will help shape dBio's vision for the future.

Transforming Sports Tech

dBio is recognized as a pioneer in integrating advanced technology with sports and health, delivering cutting-edge AI-enabled wearables that connect athletic performance with real-time health monitoring. Their mission is to provide athletes and fitness enthusiasts with the tools they need to optimize their training, recover faster, and minimize injury risks.

Hoyt's extensive experience in brand management and strategic growth is expected to be integral as dBio continues to innovate. His previous tenure at Nike saw the company grow significantly, increasing revenue in the EMEA region from $3 billion to over $10 billion. This growth was fueled by Hoyt's deep understanding of consumer needs, which he utilized to align Nike's products with the athletic community’s desires.

dBio’s Innovative Solutions

At the heart of dBio's offerings are two notable technologies: gMOTCloud, an AI-powered kinesiology wearable, and StethoCloud, a lightweight wearable stethoscope designed for continuous health monitoring. These devices not only collect detailed metrics on motion and gait but also harness cloud-based analytics and provide virtual coaching to ensure safety and effectiveness in athletic performance.

Hoyt expresses his endorsement for dBio’s technology, stating, “Throughout my career, I have been focused on enhancing athletes’ performances. Joining dBio allows me to continue this journey, leveraging their innovations to advance athlete health and wellbeing.” This aligns with dBio's strategic objectives—redefining how health and performance technology is approached in the sports industry.

Commitment to Personal Health

The complexities of athlete health management call for holistic solutions, which dBio is committed to providing. With a portfolio that boasts over 75 registered patents and a self-developed ecosystem for AI modeling, hardware, and app development, the company is positioning itself as a leader in personalized health technology suitable not only for elite athletes but also for general fitness participants, telemedicine, rehabilitation, and elder care.

Strategic partnerships with leaders from various sectors complement dBio's capabilities, enhancing their reach and effectiveness in presenting a comprehensive solution to health and performance

Hoyt’s Legacy and Future

After leaving Nike in early 2021, Hoyt didn't step back from the scene; instead, he transitioned into advisory roles with various companies, including JD Sports PLC and Mast-Jaegermeister SE. His breadth of knowledge from both corporate leadership and competitive sports background—having competed as a professional tennis player—makes him a uniquely qualified asset on dBio’s board.

As dBio expands its influence globally, Hoyt's strategic guidance is expected to play a crucial role in shaping the next generation of sports technology that meets the evolving needs of athletes.

In conclusion, Bert Hoyt's appointment as a Board Advisor at dBio marks a promising chapter for the company and the broader context of health and sports technology. With forward-thinking innovations and a commitment to athlete welfare, dBio is on the brink of significant advancements as it embraces the future of health technology in sports.